Minerva Neurosciences
NERV
33 hedge funds and large institutions have $16.3M invested in Minerva Neurosciences in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 14 reducing their positions, and 6 closing their positions.
236% more call options, than puts
Call options by funds: $225K | Put options by funds: $67K
0.31% less ownership
Funds ownership: 6.07% → 5.76% (-0.31%)
2% less capital invested
Capital invested by funds: $16.6M → $16.3M (-$275K)
6% less funds holding
Funds holding: 35 → 33 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
79% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$134K |
| 2 |
B
Bailard
Foster City,
California
|
+$18.7K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$13.1K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$11.5K |
| 5 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$9.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$281K |
| 2 |
Morgan Stanley
New York
|
-$158K |
| 3 |
Renaissance Technologies
New York
|
-$154K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$135K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$68.3K |
NERV Hedge Fund Activity: Q1 2022 in Review
33 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q1 2022, worth a combined $16.3M — down 1.7% from $16.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NERV and 4 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 3 added.
The largest buyer was Fidelity Investments, adding an estimated $134K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $281K sold.
- 33 institutional investors held Minerva Neurosciences (NERV) as of Q1 2022, down from 35 in Q4 2021.
- Funds reported $16.3M of Minerva Neurosciences stock for Q1 2022, down 1.7% quarter-over-quarter.
- 4 funds opened new Minerva Neurosciences positions in Q1 2022 and 6 closed out, a net change of -2 holders.
- The largest Minerva Neurosciences buyer in Q1 2022 was Fidelity Investments, an estimated $134K added.
- The largest Minerva Neurosciences seller in Q1 2022 was Dimensional Fund Advisors, an estimated $281K sold.
Based on aggregated 13F filings for Q1 2022.